Disc Medicine (NASDAQ:IRON) Earns “Overweight” Rating from Cantor Fitzgerald

by · The Cerbat Gem

Cantor Fitzgerald reaffirmed their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report report published on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $85.00 price target on the stock.

IRON has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a research note on Monday, September 16th. BMO Capital Markets reiterated an “outperform” rating and issued a $70.00 price objective (up previously from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Disc Medicine in a research note on Friday, August 9th. Finally, Wells Fargo & Company initiated coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $63.89.

Check Out Our Latest Report on Disc Medicine

Disc Medicine Stock Up 0.1 %

Shares of NASDAQ IRON opened at $50.56 on Tuesday. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60. The business’s 50 day moving average is $48.76 and its two-hundred day moving average is $41.46. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -14.96 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. Analysts anticipate that Disc Medicine will post -4.19 EPS for the current fiscal year.

Institutional Trading of Disc Medicine

Several institutional investors have recently modified their holdings of IRON. Frazier Life Sciences Management L.P. raised its stake in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Disc Medicine in the 2nd quarter valued at about $41,690,000. Point72 Asset Management L.P. acquired a new stake in shares of Disc Medicine in the 2nd quarter valued at about $34,318,000. Deerfield Management Company L.P. Series C boosted its position in shares of Disc Medicine by 53.8% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after buying an additional 353,382 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Read More